Episode 84 - Tord Labuda - CEO of Alzinova

On this episode of the BioHub Podcast we’re joined by the CEO of Alzinova, Tord Labuda. Alzinova are a Gothenburg-based biotech developing an Alzheimer’s vaccine that's just received FDA IND approval and will soon step into ph2 trials. Alzinova’s products have been developed using their proprietary AβCC peptide™ technology. The technology entails covalent restriction of the amyloid-β (Aβ) peptide so that it only forms the soluble (Aβ) toxins (oligomers/protofibrils) that play a central role in the disease process. Alzinova's mission is to bring true disease-modifying therapy to Alzheimer’s patients. By using the proprietary AβCC technology, Alzinova can develop therapies that are unique in that they target Alzheimer’s disease-driving toxins of Aβ (“oligomers”) specifically.